Archives 2026

Amit Shah Mourns Demise of Veteran Singer Suman Kalyanpur, Says Indian Music Has Lost a Timeless Voice

New Delhi, June 1 (BNP): Union Home Minister Amit Shah paid heartfelt tribute to legendary playback singer Suman Kalyanpur following her demise, describing her passing as a major loss to India’s music fraternity and remembering her as a voice that touched millions across generations.

Expressing grief, Shah said the Indian music industry had lost one of its most melodious and graceful voices, whose timeless songs continue to occupy a special place in the hearts of listeners.

In his tribute, the Home Minister acknowledged Suman Kalyanpur’s immense contribution to Indian cinema and music, noting that her soulful renditions and unmatched vocal elegance enriched the country’s cultural heritage over several decades.

He also conveyed condolences to her family, admirers and members of the artistic community, saying her legacy would continue to inspire generations of singers and music lovers.

Suman Kalyanpur earned recognition as one of India’s most admired playback singers, lending her voice to numerous memorable songs in Hindi and regional cinema. Her distinct singing style and emotional depth won her enduring admiration among audiences and musicians alike.

Tributes from political leaders, film personalities and fans have continued to pour in following news of her passing, reflecting the profound influence she had on Indian music and popular culture.

Her demise marks the end of an era in Indian playback music, with admirers remembering her not only for her unforgettable melodies but also for the lasting emotional connection her voice created with audiences across the country.

Anushka Sharma Celebrates RCB’s IPL Triumph With Heartwarming Gesture for Virat Kohli

Ahmedabad, June 1 (BNP): Royal Challengers Bengaluru’s (RCB) historic IPL 2026 title victory was marked by an emotional celebration off the field as actor Anushka Sharma shared a heartfelt moment with star batter Virat Kohli following the team’s triumph.

Anushka Sharma Celebrates RCB’s IPL Triumph With Heartwarming Gesture for Virat Kohli

Soon after RCB sealed their second consecutive Indian Premier League title with a victory over Gujarat Titans in Ahmedabad, Anushka was seen celebrating alongside Kohli and the team members at the Narendra Modi Stadium. In a touching moment that quickly captured public attention, she congratulated Kohli with a sweet kiss on his forehead, reflecting pride and joy over the memorable achievement.

The candid celebration soon gained traction across social media platforms, with fans praising the couple’s emotional bond and expressing admiration for the heartfelt gesture following one of the biggest moments in Kohli’s cricketing career.

Kohli, who played a match-winning unbeaten knock of 75 in the final, emerged as one of the key architects of Bengaluru’s successful title defence. His composed innings helped RCB comfortably chase the target and secure another IPL crown.

The emotional exchange between Anushka and Kohli added a personal touch to RCB’s championship celebrations, with supporters widely sharing visuals of the moment and calling it one of the standout images from the IPL 2026 final.

RCB’s title-winning campaign, coupled with Kohli’s strong performance and the post-match celebration, ensured the night remained memorable both on and off the field.

Winston Taylor Completes Historic Transatlantic Combination

Business Wire India

Winston Taylor announces today that Winston & Strawn and Taylor Wessing’s U.K.-led business have officially launched as a single combined firm, creating a premier transatlantic law firm built for the needs of the businesses, people, and markets driving capital and innovation.

 

One of the largest transatlantic firms, with more than 1,400 lawyers spanning the United States, the United Kingdom, Europe, Latin America, and the Middle East, Winston Taylor is built to meet clients’ evolving global needs for counsel.

 

 

“As Winston Taylor, we are centered on a client-first approach and will be working shoulder to shoulder with our clients at the cutting edge of industry and ingenuity,” said Chairman Steve D’Amore. “With that common purpose, we are leveraging both strength and scale by integrating our teams and offices at record speed, working at pace to create a firm that is aligned, focused, and built for the day-to-day needs of our clients as well as their breakthrough moments.”

 

 

Winston Taylor operates out of 20 offices across the major commercial centers that matter to its clients. The firm has strength and depth across its core defining capabilities of major litigation, critical transactions, strategic IP, and private wealth; and is embedded in key client sectors, including technology, media & telecommunications, life sciences & healthcare, financial services, and projects, energy & infrastructure.

 

 

“We have created a unified, transatlantic team focused on providing unparalleled service to clients and attracting the best practitioners in the major hubs of innovation and capital,” said Shane Gleghorn, Managing Partner of Europe and Middle East. “As part of this defining combination, our lawyers have already identified dozens of new cross-border opportunities to serve clients, advising global innovators in key sectors and winning work that is possible because of our newly combined footprint and capabilities.”

 

 

Now complete, Winston Taylor has brought together two firms with more than 400 years of combined history. The firm’s expanded corporate, private equity, real estate, finance, antitrust, regulatory, and private wealth capabilities will provide clients with end-to-end global business strategy and support.

 

 

Notes to Editors

 

 

About Winston Taylor

 

 

Winston Taylor is a transatlantic law firm built for the businesses, people, and markets driving capital and innovation. The firm is present in the major commercial centers that matter to global clients: the U.S., the U.K., Europe, Latin America, and the Middle East. With a team of over 1,400 lawyers, Winston Taylor brings deep experience in Major Litigation, Critical Transactions, Strategic IP, and Private Wealth; and four focus sectors: Technology, Media & Telecommunications, Life Sciences & Healthcare, Financial Services, and Projects, Energy & Infrastructure. Whatever the challenge, Winston Taylor is in the room with its clients, shoulder to shoulder in the everyday moments, and the ones that change everything.

 

 

Please visit winstontaylor.com for additional information about our services, our experience, and the sectors we serve.

 

 

About Winston & Strawn

 

 

Founded in 1853, Winston & Strawn is an Am Law 50 firm with 1,000 lawyers across 14 offices worldwide. The firm is recognized for its leadership in litigation, intellectual property, corporate and finance transactions, and regulatory work across major sectors, including technology, life sciences, and financial services.

 

 

About Taylor Wessing UK

 

 

Founded in 1782, Taylor Wessing UK is a Top 20 UK law firm with over 450 lawyers in the UK, Ireland and the Middle East. The firm is renowned for its Tier 1 intellectual property, life sciences, technology, private wealth, and private equity practices, advising clients ranging from global corporations to leading innovators and investors.

 

 

About Taylor Wessing the Netherlands and Belgium

 

 

Taylor Wessing the Netherlands and Belgium brings together its Amsterdam, Eindhoven, and Brussels offices into a fully integrated Benelux practice, with over 100 lawyers and civil-law notaries advising high-growth technology and life sciences companies, multinational corporates, and investors on corporate transactions, intellectual property, disputes, and regulatory matters.

 

 

 

 

 

Kinaxis Appoints Kristin Russel as Chief Marketing Officer

Business Wire India

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced the appointment of Kristin Russel as Chief Marketing Officer (CMO). Russel will lead Kinaxis’ global marketing organization, overseeing marketing strategy, corporate and market positioning, digital and brand marketing, communications and go-to-market initiatives.

 

Russel will also take the main stage at Kinexions, where she will discuss practical steps organizations can take to move from decisions to outcomes in an increasingly complex operating environment.

 

 

A tenured marketing executive and recognized industry leader, Russel brings deep experience scaling technology companies and building high impact brands. She joins Kinaxis from symplr, where she served as Chief Marketing Officer and led the development and execution of the company’s comprehensive marketing strategy across branding, digital and product marketing, public relations, community outreach programs, channel partnerships, and business development.

 

 

“Kristin is a proven leader with a track record of building strong brands and connecting strategy to execution,” said Razat Gaurav, Chief Executive Officer of Kinaxis. “As Kinaxis continues to expand its leadership in AI-powered supply chain orchestration and accelerate global growth, Kristin’s experience scaling enterprise technology platforms and transforming go-to-market strategy will help strengthen how we engage customers, partners, and the market.”

 

 

Russel is widely recognized for her leadership in technology and healthcare marketing. She was named one of PR Daily’s 2023 Top Women in Marketing, recognized among Becker’s Top 100 Women in Healthcare, is a two-time 2023 Stevie Award winner, and was recently named to the 2026 B2B CMO 100, recognizing marketing leaders shaping the future of B2B go-to-market strategy.

 

 

“Kinaxis is uniquely positioned at the intersection of AI-powered orchestration, enterprise decision-making and supply chain transformation at a time when organizations are rethinking how they plan and operate in an increasingly complex world,” said Russel. “I’m excited to join the team and help accelerate the company’s next phase of growth as organizations increasingly look to AI-driven technologies to make faster, more confident decisions in the face of constant change.”

 

 

Prior to symplr, Russel led marketing at Quest Analytics and Carrot Inc., driving revenue growth through brand building, demand generation, and strategic partnerships. Earlier in her career, she held senior marketing roles at Humana, Cerner, and Omnicell. She is also a successful entrepreneur, having founded the fintech company Anachron, which was later acquired by ING Bank.

 

 

About Kinaxis

 

 

Kinaxis is a leader in modern supply chain planning and orchestration, powering complex global supply chains, and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

 

 

Source: Kinaxis Inc.

 

 

 

 

 

John Crane Retrofit Helps Copper Mine Save 288,000 Litres of Sealing Water Daily

India,  June 1:  John Crane, a global leader in flow control technologies and a business of Smiths Group plc, has retrofitted a mechanical seal on a large underflow thickener slurry pump at a major copper mining operation, cutting the clean water needed for sealing by around 288,000 litres per day and supporting a move away from frequent, high-risk maintenance interventions on a production-critical asset.

Underflow thickener pumps are a key link in tailings handling, moving high-density slurry from the thickener into the tailings transport system. In this application, the Warman 550 pump operates at approximately 65% solids, where reliability is essential and any unplanned interruption can have an immediate impact on production.

Prior to the retrofit, the pump used a traditional stuffing box (packing) arrangement. In abrasive service, that approach led to accelerated wear on the shaft sleeve, with replacement required around every four months. Although the impeller and rubber liners were typically replaced annually, sleeve change-outs were major events involving a full mechanical crew working across two shifts (around 36 hours), a 100-tonne crane, and extended exposure to safety and downtime risk.

John Crane designed a mechanical seal package to be installed at the rear of the pump replacing the original stuffing box (packing) arrangement and enabling a retrofit without modifications to the pump. The scope also included an adapter sleeve to suit the shaft. To support performance in mining service, the seal uses a controlled seal-flush arrangement to maintain a clean fluid environment at the seal faces and is specified with diamond-faced materials for robustness in the event that seal-flush pressure drops and solids enter the seal chamber.

Following installation and commissioning, the sealed pump is operating well. The seal-flush system was designed around approximately 11 m³/h at 75 psi, with actual operating flow running at approximately 7.5–8 m³/h. By comparison, a parallel pump operating with packing has been consuming around 20 m³/h of water. This indicates a reduction of roughly 12 m³/h, equivalent to approximately 288 m³ (288,000 litres) per day, subject to site operating conditions.

The retrofit is designed to align maintenance with the site’s planned annual major service interval, when the impeller and liners are replaced, reducing the need for additional intrusive interventions during the year.

“Underflow thickener pumps are among the most critical assets in a mine’s tailings circuit, so customers are understandably cautious about change,” said Warren Smith, Global Mining Market Director, John Crane. “This project is a practical example of how improved sealing can reduce maintenance exposure and cut the clean water required for sealing, while supporting more predictable planned maintenance.”

This installation also represents a milestone for John Crane. With a shaft diameter of approximately 270 mm, it is the largest slurry seal sold by John Crane to date.

CBSE to Soon Activate Class 12 Re-Evaluation, Verification Portal; Students Asked to Await Official Notice

New Delhi, June 1 (BNP): The Central Board of Secondary Education (CBSE) has announced that the online portal for Class 12 post-result verification of marks and re-evaluation will be activated soon, bringing clarity to students awaiting the application process following board examination results.

CBSE to Soon Activate Class 12 Re-Evaluation, Verification Portal; Students Asked to Await Official Notice

Representational image

The update comes amid growing concerns among students over delays in the activation of post-result services, which allow candidates to seek verification of marks and request re-evaluation of answer sheets.

Responding to queries raised by students on social media platform X, CBSE confirmed that the verification and re-evaluation portal would go live shortly and stated that a detailed official announcement would follow.

CBSE to Soon Activate Class 12 Re-Evaluation, Verification Portal; Students Asked to Await Official Notice

The board had earlier indicated that the portal was expected to open during the final week of May. However, activation was reportedly deferred to ensure a secure, transparent and error-free process for handling post-result applications.

Once operational, the portal will enable eligible students to apply for various post-result services, including verification of marks, access to photocopies of evaluated answer sheets and re-evaluation of specific responses as per prescribed guidelines.

Under the verification process, CBSE examines whether all answers have been evaluated, marks correctly totalled and final scores accurately uploaded. Students dissatisfied with their performance may subsequently apply for re-evaluation, subject to eligibility norms and procedural requirements.

Officials are expected to release detailed instructions regarding application dates, service fees, timelines and submission procedures shortly after the portal is activated.

Meanwhile, students have been advised to regularly monitor official CBSE websites and notifications for updates and keep important credentials, including roll numbers and admit card details, readily available to avoid last-minute inconvenience.

CBSE officials reiterated that students are not required to take any immediate action and should wait for the formal notification before initiating post-result applications.

GIGABYTE Showcases Full-Stack AI Infrastructure from Rack-Scale Systems to Real-World Deployment at COMPUTEX 2026

Business Wire India

Following the introduction of its “Future Landing” vision, GIGABYTE Technology, a global leader in high-performance computing and AI infrastructure, brings that vision to life at COMPUTEX 2026 through a comprehensive showcase of systems, software, and real-world deployments that demonstrate how AI infrastructure is built, deployed, and operated at scale. From rack-scale AI factories and modular data centers to Physical AI workflows, clinical AI applications, and on-prem AI agents, GIGABYTE demonstrates how AI infrastructure moves beyond planning and into production.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525486787/en/

 

 

 

Rack-Scale Infrastructure, Validated for AI Factories

 

At the foundation of “Future Landing” is GIGABYTE’s expanding portfolio of rack-scale AI infrastructure designed for next-generation AI factories.

 

 

Among the latest highlights is the NVIDIA Vera Rubin NVL72, showcased as part of GIGABYTE’s broader rack-scale portfolio. Alongside its rack-scale platforms, GIGABYTE also presents GAIFA (GIGABYTE AI Factory Accelerator), a purpose-built AI factory in Taiwan where next-generation compute, high-speed networking, and NVIDIA’s software stack are integrated into a fully validated environment for system verification, workload optimization, and deployment readiness.

 

 

At the operational layer, GPM (GIGABYTE POD Manager) provides unified visibility and infrastructure-level monitoring across compute, networking, cooling, and power systems, enabling AI factories to operate and scale as a coordinated system.

 

 

Infrastructure Built for Accelerated Deployment

 

 

To accelerate deployment beyond conventional data center construction, GIGABYTE introduces GADU (GIGABYTE Accelerated Deployment Unit), a modular AI infrastructure platform that integrates high-density compute, advanced cooling, and power distribution into transportable, deployment-ready systems. Supporting direct liquid cooling and immersion cooling architectures, GADU enables organizations to expand AI capacity with significantly reduced deployment timelines while maintaining flexibility across diverse operational environments.

 

 

Together with GIGABYTE’s rack-scale systems and infrastructure software, GADU transforms infrastructure into a scalable, rapidly deployable platform.

 

 

Physical AI from Simulation to Action

 

 

Demonstrating how AI moves beyond simulation and into real-world operation, GIGABYTE presents a complete real-to-sim-to-real workflow built on NVIDIA’s full-stack AI platforms.

 

 

The workflow begins with high-fidelity digital twins built through NVIDIA OVX systems, powered by the XLS4-SX2-LAS1 platform on NVIDIA MGX™ architecture with RTX™ PRO GPUs for large-scale Omniverse simulations. AI training then advances through the G2L4-SD4-LA08 platform on NVIDIA HGX™ architecture, where synthetic data generation and reinforcement learning take place. Once validated, trained models are deployed to edge systems powered by NVIDIA Jetson for real-time robotic control, brought to life through live demonstrations alongside Isaac Sim visualizations.

 

 

Clinical AI at the Point of Care

 

 

GIGABYTE also showcases a growing clinical AI ecosystem for real-time medical inference at the point of care. Working alongside healthcare partners, GIGABYTE integrates BRIX mini PCs with AI-assisted diagnostic systems supporting bone marrow smear classification and real-time polyp detection during colonoscopy. The VFG100, an FPGA-accelerated vision platform, delivers real-time image preprocessing with ultra-low CPU overhead, while AI TOP ATOM enables local inference for pulmonary imaging analysis, meeting healthcare data privacy and compliance requirements.

 

 

Bringing AI Closer to Where Decisions Are Made

 

 

Extending AI beyond centralized infrastructure, GIGABYTE also showcases the W775 workstation and AI TOP ATOM desktop AI supercomputer for private training, model customization, and agentic AI workflows powered by NVIDIA NemoClaw.

 

 

Beyond the main showcase on the 1st floor, visitors can also explore GIGABYTE’s dedicated exhibit on the 4th floor, where AI TOP systems and consumer AI innovations demonstrate how GIGABYTE’s computing capabilities extend from AI infrastructure to everyday intelligent experiences. At COMPUTEX 2026, GIGABYTE demonstrates how “Future Landing” is turning AI infrastructure into systems that are ready, deployable, and already happening.

 

 

GIGABYTE@COMPUTEX 2026
https://www.gigabyte.com/Events/Computex
June 2-5, 2026
Taipei Nangang Exhibition Center, Hall 1
Enterprise (1F K0802) | Consumer (4F M0520)

 

 

 

 

 

PHDCCI Organizes IBC & NCLT 10 to Celebrate a Decade of Transformative Insolvency Reforms

PHDCCI Organizes IBC & NCLT 10 to Celebrate a Decade of Transformative Insolvency Reforms

PHD Chamber of Commerce and Industry (PHDCCI) successfully organized “IBC & NCLT @10 – Celebrating a Decade of Insolvency Reforms” on 30 May 2026 at Hotel Taj Mahal, New Delhi, commemorating ten years of the Insolvency and Bankruptcy Code (IBC), 2016, and the establishment of the National Company Law Tribunal (NCLT). The event brought together eminent judicial dignitaries, policymakers, regulators, insolvency professionals, financial institutions, legal experts, industry leaders, and key stakeholders to reflect on the transformative impact of India’s insolvency framework and deliberate on the future roadmap for strengthening the insolvency ecosystem.

The event was graced by Justice Ashok Bhushan, Chairperson, NCLAT; Justice Rajesh Bindal, Former Judge, Supreme Court of India; Justice M.M. Kumar, Founder President, NCLT and Former Chief Justice of the Jammu & Kashmir High Court; Dr. Anju Rathi Rana, Member Secretary, Department of Legal Affairs, Government of India; Shri Debajyoti Ray Chaudhuri, MD & CEO, National e-Governance Services Ltd. (NeSL); Shri Gyaneswar Kumar Singh, Director General & CEO, IICA and Member Secretary, BLRC; Dr. U.K. Chaudhary, Senior Advocate and President, NCLT Bar Association; Dr. M.S. Sahoo, Former Chairperson, IBBI; Mr. P.K. Malhotra, Former Secretary, Ministry of Law & Justice; Mr. Santosh Shukla, Chief General Manager, SEBI; Mr. Rajnish Kumar, Former Chairman, State Bank of India; and Hon’ble Justice Rajesh Bindal, Former Judge, Supreme Court of India, along with distinguished members of the insolvency and legal fraternity.

Addressing the gathering, Justice Ashok Bhushan described the IBC as one of India’s most significant legal and economic reforms, transforming a fragmented and delay-prone insolvency regime into a unified, creditor-driven framework focused on time-bound resolution, value maximization, and accountability. While highlighting the important role of NCLT and NCLAT in developing insolvency jurisprudence, he emphasized the need to address challenges relating to resolution timelines, institutional capacity, cross-border insolvency, and group insolvency mechanisms to further strengthen the framework.

In his address, Justice Rajesh Bindal underscored the transformative impact of the Insolvency and Bankruptcy Code (IBC) in replacing a fragmented and inefficient insolvency regime with a resolution-oriented framework focused on preserving businesses and economic value. He highlighted the significant improvement in resolution outcomes, recoveries, revival of stressed enterprises, reduction in NPAs, and enhanced credit discipline over the past decade. Emphasizing that the success of the insolvency ecosystem has been driven by collective efforts across institutions, regulators, the judiciary, financial institutions, and industry stakeholders, he called for continued strengthening of infrastructure, technology adoption, institutional capacity, and timely resolution mechanisms to support India’s vision of becoming a developed economy by 2047. He also stressed the importance of leveraging data, digital platforms, and collaborative approaches to facilitate early resolution of financial distress and further enhance the effectiveness of the insolvency framework.

Justice M.M. Kumar reflected on the challenging initial years of establishing the NCLT and recalled how the institution began functioning with limited infrastructure and resources. He noted that despite capacity constraints, NCLT successfully implemented the IBC, facilitated significant recoveries, reduced non-performing assets, and contributed to improving India’s Ease of Doing Business rankings. He also highlighted the need to ensure greater accessibility of insolvency mechanisms for MSMEs.

Speaking on the occasion, Dr. Anju Rathi Rana stated that the IBC was far more than a legislative reform and represented a fundamental shift in India’s approach to business distress and insolvency. She noted that the Code has strengthened credit culture, enhanced investor confidence, and established a structured and accountable framework for resolution while underscoring the critical role played by NCLT in its successful implementation.

Shri Debajyoti Ray Chaudhuri highlighted the transformative role of information utilities in reducing information asymmetry and strengthening creditor confidence. Referring to more than 32,000 applications involving debt of nearly ₹14 lakh crore that were resolved before admission, he observed that the IBC has significantly changed debtor behaviour by encouraging early settlements and constructive negotiations. He further reaffirmed NeSL’s readiness to support upcoming reforms through its robust Record of Default framework.

Shri Gyaneswar Kumar Singh reflected on the collaborative efforts of the government, judiciary, regulators, insolvency professionals, and industry stakeholders in shaping India’s insolvency ecosystem. Highlighting the Code’s role in strengthening financial discipline and improving credit culture, he outlined future priorities including personal insolvency, cross-border insolvency, technology-driven reforms, creditor-led restructuring, and enhanced institutional capacity.

Dr. U.K. Chaudhary praised the significant contribution of the legal fraternity in supporting the development of insolvency jurisprudence and strengthening the functioning of NCLT and NCLAT. He called for greater institutional capacity, timely appointment of members, and enhanced infrastructure to ensure faster and more effective resolution of cases.

Earlier, Dr. Jatinder Singh, Deputy Secretary General, PHDCCI, welcomed the distinguished gathering and highlighted the transformative impact of the IBC and NCLT in promoting accountability, transparency, and a rules-based economic framework. He emphasized the active role played by PHDCCI’s IBC & NCLT Committee in facilitating policy dialogue, stakeholder consultations, and industry engagement to support the evolution of India’s insolvency framework.

Mr. G.P. Madaan, Chair, IBC & NCLT Committee, PHDCCI, in the theme address, highlighted the remarkable journey of the IBC and NCLT over the last decade, noting their contribution to strengthening credit discipline, improving debt resolution outcomes, reducing NPAs, and enhancing India’s business environment. He described the ten-year milestone as a celebration of institutional resilience, economic reform, and the collective efforts of all stakeholders associated with the insolvency ecosystem.

Ms. Ranjana Roy Gawai, Co-Chair, IBC & NCLT Committee, PHDCCI, addressed the gathering and expressed gratitude to the distinguished speakers, stakeholders, and participants for their continued contribution to strengthening India’s insolvency framework.

In a landmark gathering uniting the many officials of the IBC Ecosystem, a felicitation ceremony was presided over by Mr. G P Madaan, Chair, NCLT & IBC Committee, joined by Co-Chairs Ms. Ranjana Roy Gawai, Mr. Rachit Mittal, Mr. Abhishek Anand, and Mr. Harish Taneja,  underscoring the committee’s commitment to recognizing excellence across the insolvency landscape.

The event also featured insightful addresses by Dr. M.S. Sahoo, Former Chairperson, IBBI; Mr. P.K. Malhotra, Former Secretary, Ministry of Law & Justice; Mr. Santosh Shukla, Chief General Manager, SEBI; Mr. Rajnish Kumar, Former Chairman, SBI; and Hon’ble Justice Rajesh Bindal, Former Judge, Supreme Court of India, who shared their perspectives on the achievements of the IBC, ongoing challenges, and the reforms required to strengthen the insolvency ecosystem for the next decade.

The event was also graced by many stalwarts from the IBC ecosystem including sitting and former NCLT members. The programme concluded with a felicitation ceremony honouring distinguished contributors, policymakers, judicial members, insolvency professionals, and institutional stakeholders whose efforts have been instrumental in shaping and strengthening India’s insolvency and bankruptcy framework over the past ten years.

Tamil Nadu CM Vijay to Hold Thanksgiving Meeting in Tiruchirappalli, Attendance Restricted to Pass Holders

Tiruchirappalli, June 1 (BNP): Tamil Nadu Chief Minister and Tamilaga Vettri Kazhagam (TVK) President Vijay is scheduled to visit Tiruchirappalli today to participate in a thanksgiving public meeting at the St Joseph’s College ground near Chathiram Bus Stand, organised to express gratitude to voters and supporters from the Tiruchirappalli East constituency.

Tamil Nadu CM Vijay to Hold Thanksgiving Meeting in Tiruchirappalli, Attendance Restricted to Pass Holders

The event has been arranged to acknowledge public support received during the recent Tamil Nadu Assembly elections, in which Vijay-led TVK secured a decisive mandate to form the government. Vijay had contested from two constituencies — Perambur in Chennai and Tiruchirappalli East — winning both seats before later resigning from the Tiruchirappalli East constituency after assuming office as Chief Minister.

Despite stepping down from the constituency, Vijay is expected to personally thank party workers, supporters and voters in Tiruchirappalli district during the gathering.

According to organisers, Vijay will arrive at Tiruchirappalli Airport from Chennai by a special flight before proceeding to the venue, where extensive preparations and security arrangements have been made.

Unlike a conventional mass rally, attendance at the event will be strictly regulated through QR code-enabled entry passes, with participation capped at around 5,000 people. Organisers clarified that entry will not be permitted without valid authorisation under any circumstances.

As a precautionary measure, passes were reportedly not issued to pregnant women, children, school students, senior citizens, differently-abled individuals and people with health concerns, while authorities advised such groups to avoid attending the programme.

Police and administrative officials have issued guidelines regarding designated parking areas to minimise traffic disruption near the venue. Drinking water, medical support and other basic facilities have also been arranged for attendees.

Meanwhile, party workers and members of the public unable to secure entry passes have been encouraged to follow the event through television broadcasts and live social media coverage to ensure smooth management of the programme.

The thanksgiving meeting is expected to draw political attention in Tamil Nadu as Vijay continues to consolidate his leadership following the party’s electoral success.

BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026

Business Wire India

BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs.

 

Data from three differentiated BeOne pipeline assets will be presented, including:

 

 

  • CDK4 inhibitor (BGB-43395) (poster presentation): First disclosure of anti-tumor activity in first-line (1L) HR+/HER2- metastatic breast cancer.
  • B7-H4 ADC (BG‑C9074) (rapid oral presentation): Phase 1 dose-escalation and safety expansion data in advanced solid tumors.
  • GPC3x4-1BB (BGB-B2033)bispecific antibody (rapid oral presentation): First clinical data in advanced solid tumors, including hepatocellular carcinoma (HCC), the most common type of liver cancer.

 

Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “2026 is an inflection year for BeOne’s solid tumor portfolio, marked by the encouraging data we are presenting at ASCO combined with upcoming readouts at other major congresses. These programs validate our strategy of pairing the right biology with the right modality, and support advancing several assets in different indications into pivotal trials in 2026.”

 

Selective CDK4 inhibitor shows promising efficacy and differentiated safety in first-line breast cancer (Poster Presentation: 180; June 1, 2026, 1:30 PM-4:30 PM CDT)
BeOne will present data about its highly selective CDK4 inhibitor, BGB-43395, in 1L HR+/HER2- metastatic breast cancer, in combination with letrozole, showing promising anti-tumor activity and a favorable safety profile, characterized by infrequent low-grade hematologic toxicities and manageable GI events, which were further mitigated when administered with food. Highlights include:

 

 

  • The 240 mg dose of BGB-43395 plus letrozole resulted in a confirmed overall response rate (ORR) of 68.4% (95% CI: 43.4–87.4) and unconfirmed ORR of 73.7% (95% CI: 48.8-90.9).
  • The 400 mg dose plus letrozole resulted in a confirmed ORR of 63.2% (95% CI: 38.4–83.7) and unconfirmed ORR of 73.7% (95% CI: 48.8-90.9).
  • Low levels of hematologic treatment-related adverse events (TRAEs) with Grade ≥3 neutropenia reported in 5.3% of patients at the 240 mg dose level and 0% at 400 mg, as well as low frequency of fatigue and asthenia; supports profile and validates the molecule’s high selectivity for CDK4.
  • GI TRAEs were mitigated when administered with food, all of which were Grade 1.
  • Median study follow-up was 12.5 (range, 3.1-15.2) months, 12.4 (range, 8.0-15.0) months, and 10.8 (range, 3.2-12.9) months for the 240 mg, 400 mg, and 600 mg dose groups, respectively.

 

These compelling safety and efficacy findings support the rationale to initiate a global, randomized Phase 3 clinical trial with BGB-43395 in combination with letrozole in 1L HR+/HER2- metastatic breast cancer. The trial, KANDELA-302 (NCT07492641), will begin enrolling patients this month.

 

B7-H4 ADC demonstrates encouraging efficacy supporting advancement in ovarian cancer (Rapid Oral Abstract: 3013; June 2, 2026, 9:45-11:15 AM CDT)
Data at ASCO from BeOne’s B7‑H4-targeting antibody-drug conjugate (ADC), BG‑C9074, include results from Phase 1 dose‑escalation and safety‑expansion cohorts, demonstrating a combination of early efficacy signals and a favorable tolerability profile. Highlights include:

 

 

  • At doses under consideration for future development, confirmed ORR of 45.5% and unconfirmed ORR of 54.5% in ovarian cancer (OC), and 40.0% in triple-negative breast cancer, with median study follow-up of 6.6 (range, 0.3-20.8) months.
  • Anti-tumor activity demonstrated in OC regardless of B7-H4 expression level.
  • Treatment was generally well tolerated with low rates of discontinuation at <5%; 31.5% of patients experienced Grade ≥3 TRAEs, with no Grade ≥3 nausea at 6 mg/kg adjusted ideal body weight (AIBW) and 1.2% at 8 mg/kg AIBW. Grade ≥3 neutropenia rates were 14.8% at 6 mg/kg AIBW and 34.6% at 8 mg/kg AIBW.
  • AIBW-based dosing used in the ongoing phase 1 study of BG-C9074 effectively reduced pharmacokinetic variability compared with total body weight dosing, as presented in a separate abstract (Poster 166) at ASCO.

 

These results support continued advancement of the BG‑C9074 development program, with efforts focused on early‑line OC and additional B7‑H4-expressing tumor types.

 

Potential first-in-class GPC3x4-1BB bispecific demonstrates unprecedented anti-tumor activity in heavily pre-treated HCC patients (Rapid Oral Abstract: 3016; June 2, 2026, 9:45-11:15 AM CDT)
The first clinical data (Phase 1a) for BGB-B2033, a GPC3x4-1BB bispecific antibody, will be presented in a rapid oral session highlighting the first-in-class potential of this program in advanced solid tumors, including heavily pre-treated HCC. BGB-B2033 was rationally designed to target GPC3-expressing tumors, a protein commonly expressed in HCC, the sixth most prevalent cancer and third leading cause of cancer death worldwide,1 with five-year survival rates of only approximately 20%.2

 

 

Highlights include:

 

 

  • At doses ≥300 mg, confirmed ORR was 28.9% and unconfirmed ORR was 31.6%, with median study follow-up of 4.8 (range, 0.3-15.5) months.
  • Treatment was generally well tolerated across all dose levels (1-1000 mg every three weeks [Q3W], N = 61) with no significant dose-dependent increase in rates of treatment-emergent adverse events (TEAEs):
    • 68.9% (42) of patients experienced TEAEs; of these:
      • 47.5% (29) were treatment related
      • 8.2% (5) of patients experienced Grade ≥3 TRAEs
      • 4.9% (3) were treatment-related serious adverse events
    • TEAE leading to treatment discontinuation occurred in 3.3% (2) of patients
    • Dose limiting toxicity occurred in 1.6% (1) of patients
  • TRAEs that occurred in >5% of patients were limited to increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST), both occurring at Grade ≥3 in only 1.6% of patients.

 

BGB-B2033

300 mg Q3W

 

(N=14)

600 mg Q3W

 

(N=14)

1000 mg Q3W

 

(N=10)

Confirmed ORR (complete response + partial response), n (%)

4 (28.6)

5 (35.7)

2 (20.0)

Unconfirmed ORR (complete response + partial response), n (%)

4 (28.6)

5 (35.7)

3 (30.0)*

*An additional PR (week 36) was reported at 1000 mg, with patient still on treatment, pending confirmation in the next tumor assessment

With ORR levels in heavily pretreated patients on par with the current first-line immunotherapy combination standard of care and a differentiated safety profile, BeOne is moving rapidly to advance clinical development of BGB-B2033. The Company has already announced the initiation of a potentially registration-enabling pivotal study in late-line HCC and planned expansion into earlier lines of therapy and additional tumor types, with the ambition to establish a new standard of care in this difficult-to-treat cancer.

 

Investor webcast to highlight solid tumor pipeline data at ASCO

 

 

BeOne will hold an investor webcast at 7:00 p.m. CDT/8:00 p.m. EDT, today, June 1, 2026. The Company’s leadership team, with clinical commentary by expert physicians, will highlight key solid tumor programs being presented at ASCO, share progress in BeOne’s global R&D portfolio, and outline the strategies and capabilities supporting the Company’s continued growth trajectory.

 

 

Webcast access details are available in the Investors section of BeOne’s website at http://ir.beonemedicines.com, https://hkexir.beonemedicines.com, and https://sseir.beonemedicines.com. An archived webcast will be available on the Company’s website.

 

 

About BGB-43395, a CDK4 inhibitor
BGB-43395 is an investigational cyclin-dependent kinase (CDK) 4 inhibitor being studied in a global clinical development program in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The program includes KANDELA-302 (NCT07492641), a randomized Phase 3 clinical trial, initiated in Q2 2026 in first-line metastatic HR+/HER2- breast cancer. BGB-43395 is highly potent and selective CDK4 inhibitor and has the potential to reduce the dose-limiting hematologic toxicities that exist with the current CDK4/6 standard of care and may improve tolerability and enable deeper CDK4 inhibition.

 

 

About BG-C9074, a B7-H4-targeting ADC
BG-C9074, an investigational topoisomerase I inhibitor ADC that targets the B7-H4 protein, which is broadly expressed in breast and gynecologic cancers, is designed with an innovative drug linker to deliver a potent cancer-killing drug directly to the cancer cells. In a Phase 1 study of BG-C9074 (NCT06233942), patients with advanced solid tumors, irrespective of B7-H4 expression, received BG-C9074 every 3 weeks in escalating doses from 1 to 9 mg/kg. A subsequent safety expansion cohort received BG-C9074 in doses ranging from 4 to 8 mg/kg. Endpoints included safety, recommended dose for expansion, preliminary antitumor activity and pharmacokinetic measures.

 

 

About BGB-B2033, a GPC3x4-1BB bispecific antibody
BGB-B2033 is a bispecific antibody targeting GPC3 (glypican 3), a tumor-specific antigen highly expressed in hepatocellular carcinoma (HCC),3 and 4-1BB, a co-stimulatory receptor associated with T-cell activation and tumor reactivity in HCC.4 The molecule has been designed with reduced antibody-dependent cellular cytotoxicity (ADCC) to prevent systemic toxicity. BGB-B2033 is being investigated in a Phase 1 study (NCT06427941) in patients with GPC3-expressing advanced solid tumors with at least one prior line of therapy. Patients received BGB-B2033 every 3 weeks in eight escalating dose levels from 1 to 1000 mg, with various safety and anti-tumor activity endpoints. In December 2025, the FDA granted Fast Track Designation to BGB-B2033 for the treatment of HCC, followed by Orphan Drug Designation in March 2026.

 

 

About BeOne
BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

 

 

Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding its solid tumor pipeline; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.

 

 

To access BeOne media resources, please visit ourNewsroomsite.

 

 

   

1 Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol. 2021 Jul;12(Suppl 2):S361-S373. doi: 10.21037/jgo.2020.02.08. PMID: 34422400; PMCID: PMC8343080.

2 National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Accessed April 2026.

3 Fanching Lin et al. Novel GPC3-targeting radiopharmaceutical therapy for hepatocellular carcinoma. J Clin Oncol 42, 525-525(2024).DOI:10.1200/JCO.2024.42.3_suppl.525

4 Kim DY et al. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. Hepatology, VOL. 71, NO. 3, 2020. https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.30881